Ribonuclease H2 mutations induce a cGAS/STING-dependent innate immune response

Karen J Mackenzie1, Paula Carroll1, Laura Lettice1, Žygimantë Tarnauskaitë2, Kaalak Reddy1, Flora Dix1, Ailsa Revuelta1, Erika Abbondati2, Rachel E Rigby1,†, Björn Rabe1,‡, Fiona Kilanowski1, Graeme Grimes1, Adeline Fluteau1, Paul S Devenney1, Robert E Hill1, Martin AM Reijns1 and Andrew P Jackson1,*

Abstract
Aicardi–Goutières syndrome (AGS) provides a monogenic model of nucleic acid-mediated inflammation relevant to the pathogenesis of systemic autoimmunity. Mutations that impair ribonuclease (RNase) H2 enzyme function are the most frequent cause of this autoinflammatory disorder of childhood and are also associated with systemic lupus erythematosus. Reduced processing of either RNA:DNA hybrid or genome-embedded ribonucleotide substrates is thought to lead to activation of a yet undefined nucleic acid-sensing pathway. Here, we establish Rnaseh2A1274T knock-in mice as a subclinical model of disease, identifying significant interferon-stimulated gene (ISG) transcript upregulation that recapitulates the ISG signature seen in AGS patients. The inflammatory response is dependent on the nucleic acid sensor cyclic GMP-AMP synthase (cGAS) and its adaptor STING and is associated with reduced cellular ribonucleotide excision repair activity and increased DNA damage. This suggests that cGAS/STING is a key nucleic acid-sensing pathway relevant to AGS, providing additional insight into disease pathogenesis relevant to the development of therapeutics for this childhood-onset interferonopathy and adult systemic autoimmune disorders.

Keywords Aicardi–Goutières syndrome; autoinflammation; cGAS-STING; ribonuclease H2

Introduction
Nucleic acid sensing is a key element of antimicrobial immunity (Wu & Chen, 2014). Diverse nucleic acid sensors act as pattern recognition receptors (PRRs), initiating innate immune responses necessary to protect against pathogens containing a diverse range of nucleic acid species (Wu & Chen, 2014). Such innate immune activation, arising from sensing of cellular nucleic acids, is also implicated in autoimmune disease, most notably systemic lupus erythematosus (SLE) (Wahren-Herlenius & Dorner, 2013).

The autoinflammatory disorder Aicardi–Goutières syndrome (AGS) has provided important insights into mechanisms underlying nucleic acid-mediated inflammation (Crow & Manel, 2015). AGS typically presents in infancy following a period of normal development, with sterile pyrexia, irritability, seizures and loss of developmental milestones (Crow & Livingston, 2008). Persisting severe physical and intellectual disability is frequent, and extra-neurological features can include vasculitic skin lesions (Crow & Livingston, 2008; Crow et al., 2015). Increased type 1 interferon activity is most reliably detected during the early stages of the disease (Crow et al., 2015). However, upregulated interferon-stimulated gene (ISG) transcripts in blood have proven to be the most robust diagnostic biomarker in AGS patients, and an “ISG signature” often persists long after the initial stages of disease (Rice et al., 2013; Crow et al., 2015).

Although AGS is a monogenic disorder, it is genetically heterogeneous, with seven genes implicated to date, encoding several nucleic acid processing enzymes and a cytosolic nucleic acid sensor. These comprise the RNASEH2A, RNASEH2B and RNASEH2C proteins of the RNase H2 endonuclease complex (Crow et al., 2006b) as well as TREX1, SAMHD1, ADAR and IFIH1 (Crow et al., 2006a; Rice et al., 2009, 2012, 2014). Heterozygous mutations in the three RNase H2 genes (Günther et al., 2015) and TREX1 (Lee-Kirsch et al., 2007) are also associated with systemic lupus erythematosus.

Partial loss-of-function biallelic mutations in the RNase H2 genes are the major cause of AGS, accounting for over half of all cases (Crow et al., 2015). RNase H2 is ubiquitously expressed and functions alongside RNase H1 to degrade cellular RNA:DNA heteroduplexes. Although the exact in vivo substrates of these nucleases remain to be identified, they are thought to act on RNA:DNA hybrids such as those arising during nuclear DNA replication and R-loop formation (Cerritelli & Crouch, 2009). Unlike RNase H1, RNase H2 also cleaves and initiates the removal of single ribonucleotides.

1 MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, The University of Edinburgh, Edinburgh, UK
2 Roslin Institute, The University of Edinburgh, Edinburgh, UK
*Corresponding author. Tel: +44 131 651 8500, Fax: +44 131 467 8456; E-mail: andrew.jackson@igmne.ed.ac.uk
†Present address: MRC Human Immunology Unit, Radcliffe Department of Medicine, MRC WIMM University of Oxford, Oxford, UK
‡Present address: Institute of Biochemistry, Christian-Albrechts-University of Kiel, Kiel, Germany
embodied in DNA (Eder et al., 1993; Rydberg & Game, 2002), a process known as ribonucleotide excision repair (REK) (Sparks et al., 2012). RNase H2 is essential for mammalian genome stability, with complete loss of RNase H2 resulting in embryonic lethality (Reijns et al., 2012; Hiller et al., 2012).

Intracellular accumulation of aberrant nucleic acid species is believed to trigger intrinsic nucleic acid sensors initiating autoimmune in AGS (Crow & Manel, 2015). Trex1−/− and Adar1−/− mouse models have, respectively, implicated the cGAS-STING pathway (Ablasser et al., 2014; Ahn et al., 2014a; Gray et al., 2015; Gao et al., 2015) and MDA5/IFIH1 (Liddicoat et al., 2015) pathways in driving immune activation. However, to date, an immune phenotype in mice has not been described for mutations in any of the RNase H2 genes. It therefore remains to be determined whether a similar pathophysiological mechanism underlies RNase H2 deficiency, and consequently, the nature of the activated immune pathway in the majority of AGS patients is yet to be defined.

Here, we identify a sub-clinical phenotype of ISG induction in a mouse model of the RNASEH2B-A177T mutation, the single most common missense mutation found in AGS patients. We demonstrate that this is dependent on the cGAS/STING pathway, consistent with a common missense mutation found in AGS patients. We demonstrate immunity in AGS (Crow & Manel, 2015).

Results

A hypomorphic RNase H2 mouse model for Aicardi–Goutières syndrome

A mouse model was created by targeted knock-in of the A174T missense mutation (c.520G>A) into exon 7 of Rnaseh2b in mouse embryonic stem cells using homologous recombination (Fig 1A–D and Appendix Fig S1). A C57BL/6J congenic Rnaseh2b+/A174T/A174T mouse line was established using these cells, orthologous to the most common pathogenic mutation identified in patients with AGS, RNASEH2B-A177T. This mutation resulted in reduced cellular levels of all three RNase H2 subunits in Rnaseh2b+/A174T/A174T mouse embryonic fibroblasts (MEFs) and RNASEH2B-A177T/A177T AGS patient lymphoblastoid cells (LCLs) (Fig 1E). This is consistent with reduced RNase H2 complex stability predicted from structural and biochemical studies that showed that the RNASEH2B-RNASEH2C interaction interface is disrupted by the A177T substitution (Figiel et al., 2011; Reijns et al., 2011). Cellular RNase H2 activity was also significantly reduced to 30 ± 2% activity in Rnaseh2b+/A174T/A174T MEFs (Fig 1F and G) and 49 ± 3% activity in RNASEH2B-A177T/A177T LCLs (Fig 1H), assessed against an embedded ribonucleotide substrate. More pronounced reduction in the mouse cells may be explained by the presence of a neomycin selection cassette between exon 6 and 7, causing reduced Rnaseh2b transcript levels (~60% of wild type; data not shown).

Despite marked impairment of RNase H2 activity, Rnaseh2b+/A174T/A174T mice had no overt phenotype and remained healthy when aged. Full pathological examination of brain, liver, heart, lungs, thymus, spleen, gastrointestinal tract, kidneys, skin and tongue from mice (n = 9) did not detect histological features of inflammation, infection or neoplasia at 1 year (data not shown). In particular, there was no evidence of intracranial calcification, leukodystrophy, chilblain vasculitis or cardiomyopathy, clinical features associated with AGS in humans (Crow et al., 2015).

Notably, histopathological signs of inflammation are also not evident in Samhd1−/− mice, although activation of innate immune signalling does occur, with ISG upregulation evident (Behrendt et al., 2013; Rehwinkel et al., 2013). We therefore investigated whether this was also the case in Rnaseh2b+/A174T/A174T mice.

ISG upregulation is present in tissues from Rnaseh2b+/A174T/A174T mice

Since an ISG transcriptional response is the most robust biomarker of inflammation in human patients (Rice et al., 2013), we performed RT–qPCR for a panel of AGS-relevant ISGs on RNA extracted from adult Rnaseh2b+/A174T/A174T mouse tissues. A broad upregulation of ISGs was detected in heart (Fig 2A) along with significant induction of a subset of ISGs in the kidney (Fig 2B), but without any ISG response evident in brain (Fig 2C). The twofold to fourfold induction of ISGs we observed in Rnaseh2b+/A174T/A174T heart tissue is comparable to the fourfold to sevenfold induction seen in Samhd1−/− mouse tissue (Rehwinkel et al., 2013). While an overt inflammatory phenotype is seen in Trex1−/− mice (Morita et al., 2004; Gall et al., 2012), pathological signs of neuroinflammation are not evident, although ISG upregulation in brain tissue can be detected (Pereira-Lopes et al., 2013). Given that the autoinflammatory process appears to initiate in the Trex1−/− heart (Gall et al., 2012), there are similarities between the pattern of inflammation in Trex1−/− mice and the ISG tissue expression pattern in Rnaseh2b+/A174T/A174T mice.

A proinflammatory response in Rnaseh2b+/− MEFs

We next investigated whether the observed ISG induction was directly attributable to reduced RNase H2 activity. To address this, we examined cells from a second independent mouse line carrying a null allele of Rnaseh2b (Rnaseh2b−/−/−), derived from the EUCOMM knockout-first Rnaseh2b−/−/− allele, from which exon 5 of Rnaseh2b had been excised by Cre recombinase. Given the early embryonic lethality of Rnaseh2b−/−/− mice (Reijns et al., 2012), mouse embryonic fibroblasts (MEFs) were generated on a p53−/− background. Hereafter, we will refer to the resulting Rnaseh2b+/−/− mice (Rnaseh2b+−/− and Rnaseh2b+/−/−/−) simply as Rnaseh2b+/− and Rnaseh2b−/−, respectively. Loss of RNase H2 activity in Rnaseh2b−/− cells was confirmed (Fig 3A).

Significant upregulation of ISG transcripts was again apparent, on comparing six independent Rnaseh2b−/− MEF lines with four Rnaseh2b+/−/− control MEF lines (Fig 3B and Appendix Fig S2A). To further characterise the nature of the response, two of the Rnaseh2b−/− MEF lines with stronger ISG upregulation were compared to control lines by gene expression microarray (Fig 3C and Appendix Table S1). Of the 29 upregulated genes achieving genome-wide significance, 17 were documented ISGs and activation of non-ISG immune response pathways was not evident. In particular, there was significant induction of two ISGs encoding proinflammatory cytokines: Ccl5 (P = 0.0067) and Cxcl10 (P = 0.039). Upregulation of both transcripts was confirmed by RT–qPCR, and ELISA of culture supernatants from all six Rnaseh2b−/− lines demonstrated significantly increased CCL5 and CXCL10 secretion (Fig 3D and E,
**Figure 1.** RNase H2 complex levels and enzymatic activity are reduced in Rnaseh2b<sup>A174T/A174T</sup> mouse and RNASEH2B<sup>A177T/A177T</sup> AGS patient cells.

A. Targeted mutagenesis of the Rnaseh2b gene. Top: A 7-kb region of the Rnaseh2b genomic locus; black boxes, exons 6 (ex6) and 7 (ex7). Middle: NotI/SalI restriction fragment of the targeting construct, comprising 4.5 kb of genomic DNA and a neomycin selection cassette (Neo) flanked by loxP sites (triangles). (Bottom) Targeted locus containing exon 7 with the c.520G>A mutation (ex7*). Red arrowheads, primers used to confirm correct targeting. Red bar, 400-bp probe for Southern blotting.

B. Southern blotting confirms successful targeting. Introduction of an additional EcoRI site results in a 4.1-kb restriction fragment detectable by Southern for targeted ES cells (A174T/+), but not for parental DNA (+/+).

C. Capillary sequencing for Rnaseh2b<sup>A174T</sup> and Rnaseh2b<sup>A174T/A174T</sup> DNA confirmed the presence of the introduced missense mutation.

D. Mouse genotyping by multiplex PCR. Top: A 221-bp PCR product is present in wild-type mice (+/+); the Rnaseh2b<sup>A174T</sup> allele (also) gives a 460-bp product. Bottom: Position of forward (x) and reverse primers (y, z).

E. Immunoblotting demonstrates depletion of all three RNase H2 protein subunits in Rnaseh2b<sup>A174T/A174T</sup> MEFs and RNASEH2B<sup>A177T/A177T</sup> LCLs. Representative of three independent experiments.

F. Schematic showing enzyme activities attributed to RNase H1 and RNase H2 (DNA blue, RNA red).

G. Mouse

H. Human

RNA:DNA hybrid cleavage

RNA:DNA

Ribonucleotide Excision Repair (RER)

**Relative substrate conversion (%)**

Wildtype | Rnaseh2b<sup>A174T/A174T</sup> | Rnaseh2b<sup>A177T/A177T</sup>

Control 1 | Control 2 | A177T/A177T

RNA:DNA | DRD:DNA | RNA:DNA | DRD:DNA

Source data are available online for this figure.
and Appendix Fig S2B). Notably, these cytokines have previously been implicated in AGS neuroinflammation in humans (van Heteren et al., 2008; Takanohashi et al., 2013; Cuadrado et al., 2015). We therefore concluded that impaired RNase H2 activity in vitro and in vivo results in a similar inflammatory response to that observed in patients with AGS, and like for Trex1 deficiency (Gall et al., 2012) is present in non-immune cells.

**ISG activation is dependent on the cGAS-STING nucleic acid-sensing pathway**

We next sought to determine the nucleic acid-sensing pathway responsible for ISG induction in Rnaseh2b<sup>−/−</sup> cells. Three pathways have recently been implicated in the sensing of RNA: DNA hybrids: TLR9 (Rigby et al., 2014), cGAS-STING (Mankan et al., 2014) and the NLRP3 inflammasome (Kailasan Vanaja et al., 2014). We therefore postulated that one of these nucleic acid sensors would be responsible for the ISG signature, given that RNase H2 is the major enzyme degrading RNA:DNA hybrids in mammalian cells (Büsen, 1980; Reijns et al., 2012). However, as IL-1β and IL-18 were both undetectable in culture supernatants from Rnaseh2b<sup>−/−</sup> cells (data not shown), an inflammasome-mediated response was unlikely. While the observed ISG induction would be consistent with TLR9 activation, signalling is impaired by deficient proteolytic processing of the receptor in MEFs (Ewald et al., 2008), and we therefore prioritised assessment

**Figure 2. Increased ISG expression in tissues from Rnaseh2b<sup>A174T/A174T</sup> mice.**

A Transcript levels of multiple ISGs are significantly elevated in heart.

B Transcript levels of a subset of ISGs are significantly increased in kidney.

C No ISG upregulation is evident in the brain.

Data information: ISG transcript levels determined by RT–qPCR normalised to transcript levels of the housekeeping gene HPRT (Oas1a was undetectable in brain). Each data point represents the mean of technical replicates of tissue RNA from a single mouse. n = 9 nine-month-old Rnaseh2b<sup>A174T/A174T</sup> mice and n = 4 age-matched control wild-type C57BL/6J mice. Horizontal line, mean; error bars, SEM. *P < 0.05, **P < 0.01, two-tailed t-test.
of the cGAS-STING pathway. We performed siRNA depletion of cGAS in \textit{Rnaseh2b}^{-/-} MEFs and found that cGAS depletion significantly abrogated the ISG response and CCL5 production (Fig 4A). siRNA depletion of STING, the adaptor associated with cGAS sensing, also significantly reduced ISG induction and CCL5 secretion (Fig 4A), implicating the cGAS/STING-sensing pathway in innate immune activation in \textit{Rnaseh2b}^{-/-} cells. The siRNA knock-down was specific to cGAS and STING, respectively (Fig 4A), and cells remained fully responsive to poly(I:C) (Appendix Fig S3).

To substantiate that cGAS is required for ISG induction, CRISPR/Cas9 genome editing was performed to knock out the cGAS gene in \textit{Rnaseh2b}^{-/-} MEFs. \textit{Rnaseh2b}^{-/-} MEF clones in which cGAS deletion had not occurred were also identified, to act as experimental controls. While ISG transcript upregulation and cytokine production...
Figure 4.

The EMBO Journal

Ribonuclease H2 mutations and the cGAS-STING pathway

Karen J Mackenzie et al
et al with embedded ribonucleotides may accumulate as a consequence and RNA:DNA hybrids (Mankan et al, 2016). To address these possibilities, we determined the cGAS ligand present in RNase H2-deficient cells.

Loss of RNase H2-specific activity results in ISG induction

Finally, the fact that both dsDNA (Sun et al, 2013; Gao et al, 2013) and RNA:DNA hybrids (Mankan et al, 2014) can bind and activate the cytoplasmic nucleic acid sensor cGAS prompted us to consider the origin of the cGAS ligand present in RNase H2-deficient cells. Abrogated RNase H2 function could give rise to cytosolic accumulation of RNA:DNA heteroduplexes as a consequence of reduced RNA: DNA degradation of structures such as R-loops or active retroelements/endogenous retroviruses (Chom et al, 2013; Rigby et al, 2014; Moelling & Broecker, 2015). Alternatively, cytoplasmic DNA with embedded ribonucleotides may accumulate as a consequence of impaired RER that resulted in genome instability (Reijns et al, 2012; Hiller et al, 2012). To address these possibilities, we performed complementation experiments in RNase H2 null cells, to establish which enzymatic activity was associated with the proinflammatory response.

RNaseh2b−/− cells were complemented by retroviral transduction of either Rnaseh1 or Rnaseh2b, respectively, to reconstitute cellular RNase H activity or RNase H plus RER activity. Overexpression of RNase H1 in RNaseh2b−/− cells restored cellular enzyme activity against RNA:DNA hybrids to 81 ± 10% of the level seen in RNaseh2b+/+ cells (Fig 5A), but did not alleviate DNA damage (Fig 5B and C). Complementation with RNaseh2b reconstituted activity against both types of substrates (Fig 5A) and also returned DNA damage to levels seen in RNaseh2b+/+ cells (Fig 5B and C). Reconstitution with RNaseh2b was able to reduce cytokine and ISG responses close to wild-type levels (Fig 5D–F), while RNaseh1 complementation did not (Fig 5D–F). While some reduction was seen in CXCL10, ISG expression in RNaseh1 complemented cells was otherwise the same, if not greater than, in parental RNaseh2b−/− cells. cGAS-dependent ISG induction in RNaseh2b−/− cells is therefore associated with DNA damage and loss of RNase H2-specific activity, rather than an overall reduction in cellular activity against RNA:DNA hybrids.

Discussion

Here, we establish that RNase H2 deficiency leads to a proinflammatory response which is dependent upon the cGAS/STING pathway. The resulting ISG transcriptional response and induction of proinflammatory cytokines are consistent with cell-intrinsic innate immune activation. ISG activation varied between tissues, which may explain why such transcriptional changes were not reported...
Figure 5.

A) RNA:DNA

pmol/min converted substrate

B) 53BP1

Rnase2b<sup>++</sup> (Parental) Rnase2b<sup>−−</sup>

Rnase2b<sup>−−</sup> +EGFP +H1 +H2B

B) 53BP1

Rnase2b<sup>++</sup> (Parental) Rnase2b<sup>−−</sup>

Rnase2b<sup>−−</sup> +EGFP +H1 +H2B

C) 53BP1 foci

% cells with >5 53BP1 foci

D) CCL5

CCL5 (pg/ml)

E) CXCL10

CXCL10 (pg/ml)

F) IFIT1

Expression normalised to HPRT

IFIT3

Expression normalised to HPRT

OAS1A

Expression normalised to HPRT

Figure 5.
previously in Rnaseh2b−/− or Rnaseh2b<sup>rmi/a</sup>/<sup>rmi/a</sup> embryos (Reijns et al., 2012; Hiller et al., 2012). The precise factors determining tissue-specific cGAS activation are currently unclear, but could include the sensitivity of the cGAS/STING pathway in particular cell types, their level of cell proliferation, the rate of accumulation of immunogenic nucleic acids and the counteracting influences of cellular processes degrading such nucleic acids.

Despite tissue-specific ISG upregulation, Rnaseh2b<sup>A174T/A174T</sup> mice have a subclinical phenotype without any overt inflammatory pathology, and so, like all other AGS mouse models do not recapitulate the neuroinflammation seen in human AGS patients (Rabe, 2013; Behrendt & Roers, 2014). It will therefore be important to confirm that the innate immune pathways implicated in Trex1, Adar1 and now Rnase H2 deficiency, through the use of mouse models, are also relevant to the human autoimmune-inflammatory phenotype in AGS patients in whom these genes are affected. Samhd1<sup>−/−</sup> mice, like Rnaseh2b<sup>A174T/A174T</sup> mice, display an ISG response in the absence of detectable pathology (Behrendt et al., 2013; Rehwinkel et al., 2013). In contrast a strong ISG response in Adar1 null or editing-deficient mice is associated with embryonic lethality (Mannion et al., 2014; Liddicoat et al., 2015; Pestal et al., 2015), and with autotoxic murine cardiomyopathy and multi-tissue involvement in Trex1<sup>−/−</sup> mice (Morita et al., 2004; Stetson et al., 2008; Gall et al., 2012). The variation in severity between different AGS gene mouse models remains unexplained, although it may be meaningful that mutations in human RNASEH2B are associated with the least severe disease course, with AGS onset generally in infancy, in contrast to the prenatal/neonatal onset more commonly seen in TREX1 patients (Crow et al., 2015). Also, additional triggers, such as viral infection, have been proposed to be relevant to the pathogenesis of AGS (Crow & Manel, 2015). Reports of marked phenotypic variability in sibling pairs with identical RNASEH2B or RNASEH2C mutations (Vogt et al., 2013; Tüngler et al., 2014) are consistent with the possibility of such environmental factors impacting on disease severity. The Rnaseh2b<sup>A174T/A174T</sup> mouse and other models provide an opportunity for future investigation of these aspects.

Identification of the precise source of the immunogenic nucleic acids responsible for the inflammatory phenotype remains central to providing further mechanistic insight. Dependence of the ISG response in RNase H2- and Trex1-deficient mouse cells on the cGAS/STING pathway suggests that accumulation of cytoplasmic DNA is common to both TREX1 and RNase H2 AGS, given that DNA is the canonical ligand for cGAS (Sun et al., 2013; Gao et al., 2013). Our complementation experiments would favour this possibility, as normalising cellular enzymatic activity against RNA:DNA hybrids does not rescue the proinflammatory response. However, immunogenic RNA:DNA hybrids cannot be completely excluded, given that some hybrids might be specifically degraded by the RNase H2 enzyme (Chon et al., 2013), although the mechanism for such differential substrate specificity for RNase H1 and H2 enzymes is currently unclear.

So far, we have been unable to ascertain whether cytoplasmic double-stranded nucleic acids accumulate in RNase H2-deficient cells. However, given that impaired RER causes reduced genome stability, DNA fragments resulting from DNA strand breaks are a potential origin of immunogenic cytoplasmic DNA (Ahn et al., 2014b; Hartlova et al., 2015; Shen et al., 2015), while an alternative source could be reverse-transcribed retroelements, which are known to be activated upon DNA damage (Farkash & Luning Prak, 2006). Irrespective of the chemical nature of the ligand, our observation that cGAS plays a central role in the ISG response in Rnase H2 deficiency provides further impetus for defining the source of the immunogenic nucleic acids. While cytoplasmic DNA was first detected in 2007 in Trex1<sup>−/−</sup> cells, even here the precise origin still remains elusive, with conflicting evidence supporting either endogenous retroviruses/retroelements (Stetson et al., 2008) or genome instability (Yang et al., 2007). Purification of the responsible immunostimulatory nucleic acids could provide the solution; however, the specific isolation of such low-abundant cytoplasmic nucleic acids remains a formidable technical challenge. This has precluded a definitive answer to date, but may be aided by implicating cGAS as the nucleic acid sensor binding immunogenic nucleic acids in both Trex1- and Rnase H2-deficient cells, informing potential future biochemical strategies.

In summary, our findings implicate the cGAS-STING pathway in Rnase H2 AGS and, together with the previously attributed role in Trex1 deficiency, suggest it is the most common signalling pathway driving inflammation in AGS, relevant also to the pathogenesis of SLE (Lee-Kirsch et al., 2007; Günther et al., 2015). Targeting this pathway therefore represents a relevant therapeutic strategy for the treatment of this childhood interferonopathy and related adult-onset autoimmune conditions.

### Materials and Methods

#### Generation of Rnaseh2b<sup>A174T</sup> ES cells

Gap repair was used to retrieve a genomic fragment of 4.5 kb from BAC bMQ454F14 (Source Bioscience Lifesciences), which included exon 6 and 7 of the mouse Rnaseh2b locus (nucleotides 62977197-62981727 of Chr14, Ensembl release 64). Subsequent bacterial recombination was used to insert a neomycin cassette flanked by loxp sites between exon 6 and 7, generating a targeting vector with two external homology arms of 2.8 kb and 1.7 kb. A point mutation c.520G>C (A174T) was inserted into exon 7 of mouse Rnaseh2b by site-directed-mutagenesis (Quick-change, Agilent Technologies). After linearisation and vector backbone removal by digestion with NotI and SalI, and electroporation/purification by Elutrap, the targeting cassette was electroporated into 129/Ola E14Tg2Aiv embryonic stem cells. Southern blotting and long-range PCR were used to identify correctly targeted clones. Capillary sequencing was performed to ensure the presence of the c.520G>C mutation and absence of other coding changes. The ES cell clone was karyotyped before injection into C57BL/6J mouse blastocysts.

#### Mice

Rnaseh2b<sup>A174T</sup>

Male chimera results from blastocyst injection with Rnaseh2b<sup>A174T/+</sup> ES cells were crossed to C57BL/6J females, giving rise to heterozygous Rnaseh2b knock-in mice carrying the A174T mutation (Rnaseh2b<sup>rmi2-hgu-A174T</sup>, elsewhere referred to as Rnaseh2b<sup>tm1a</sup>-<sup>A174T</sup>). These were backcrossed to F11 on the C57BL/6J
background to establish congenericity and subsequently maintained as a homozygous mutant line. C57Bl/6J control mice were bought in at 4–6 weeks of age from the same source as those used in backcrossing, to ensure genetic matching to a level of > 99.97% identity. All mice were housed in the same facility in the same room in conventional cages and fed the same water and food until they were analysed. Murine data were analysed unblinded to genotype. Sample sizes of 3–7 mice per group were similar to previous studies.

**Rnaseh2<sup>2</sup>**

Knockout-first Rnaseh2<sup>b</sup> mice were generated by blastocyst injection of the Rnaseh2<sup>b<sup>2</sup>ES cell clone EPD0087_A402 (EUCOMM ID: 24441) and crossing of male chimera to C57BL/6J females. The Rnaseh2<sup>b<sup>2</sup>ES cell clone was in which Cre recombinase is under control of a chicken β-actin promoter (Araki et al., 1995; Kleinjan et al., 2006) to excise Rnaseh2 exon 5. The resulting Rnaseh2<sup>b<sup>2</sup>b<sup>5<sup>1</sup></sup>+/− mice were maintained on the C57BL/6J background. The phenotype of Rnaseh2<sup>b<sup>2</sup>b<sup>5<sup>1</sup></sup>+/− embryos was indistinguishable from that previously described for Rnaseh2<sup>b<sup>2</sup>b<sup>5<sup>1</sup></sup>f<sup>2</sup>OE202X/E202X</sup> embryos (Reijns et al., 2012).

**Other strains**

Ttp53<sup>s<sup>1</sup></sup> mice on the C57BL/6J background have been described previously (Jacks et al., 1994) and were kindly provided by Andrew Wood, University of Edinburgh. Interbreeding with Rnaseh2<sup>b<sup>2</sup>b<sup>5<sup>1</sup></sup>+/− mice was used to generate Rnaseh2<sup>b<sup>2</sup>b<sup>5<sup>1</sup></sup>+/− p53<sup>−/−</sup> and Rnaseh2<sup>b<sup>2</sup>b<sup>5<sup>1</sup></sup>+/− p53<sup>−/−</sup> MEFs.

Sting/Myps<sup>−/−</sup> mice on the C57BL/6J background have been described previously (Jin et al., 2011) and were kindly provided by Jan Rewinkel, University of Oxford, with the consent of John Cambier, University of Colorado SOM and National Jewish Health. Interbreeding with Rnaseh2<sup>b<sup>2</sup>b<sup>5<sup>1</sup></sup>A<sup>1777</sup>A<sup>1777</sup>/A<sup>1747</sup>A<sup>1747</sup>/A<sup>1747</sup> Sting<sup>−/−</sup> mice. Mbf2<sup>b<sup>1</sup></sup>+/+MEFs derived from C57BL/6NTac-Mbf2<sup>b<sup>1</sup></sup>+/+ (EUCOMM) were a kind gift from Jan Rehwinkel, University of Oxford. These mice were originally obtained from the Institute Clinique de la Souris through the European Mouse Mutant Archive.

All mouse studies were conducted according to UK Home Office regulations under a UK Home Office project licence.

**Genotyping**

DNA was extracted from earclips (boiled in 50 μl 25 mM NaOH, 0.2 mM EDTA for 30 min at 95°C, cooled and then neutralised with 50 μl 40 mM Tris base) or embryos (tail tips treated with DirectPCR Lysis Reagent (Viagen) according to the manufacturer’s instructions). All genotyping PCRs were performed using a multiplex three-primer strategy and Taq ReddyMix PCR Master Mix (Thermo Scientific), as previously described for Rnaseh2<sub>b<sup>2</sup>b<sup>5<sup>1</sup></sup>/E202X/E202X</sub> (Reijns et al., 2012) and p53<sup>−/−</sup> (Jacks et al., 1994). For Rnaseh2<sub>b<sup>2</sup>b<sup>5<sup>1</sup></sup>+/−, Sting/Myps<sup>−/−</sup> as well as all other primers and product sizes, see Appendix Table S2.

**Generation of murine embryonic fibroblast lines and assessment of innate immune activation**

Independent Rnaseh2<sup>b<sup>2</sup>b<sup>5<sup>1</sup></sup>A<sup>1747</sup>A<sup>1747</sup>/A<sup>1747</sup>A<sup>1747</sup></sup> and Rnaseh2<sup>b<sup>2</sup>b<sup>5<sup>1</sup></sup>+/− MEFS lines were generated from individual E13.5 embryos. After removing the head and internal organs, the embryos were mechanically dissociated in growth medium (DMEM, 10% FCS, 50 μl penicillin and 50 μg/ml streptomycin, 0.1 mM β-mercaptoethanol). Resulting suspensions were grown at 37°C, 5% CO2 and 3% O2, and non-adherent cells removed after 24 h. MEFS were subsequently maintained and passaged under the same conditions. Independent Rnaseh2<sup>b<sup>2</sup>b<sup>5<sup>1</sup></sup>+/− p53<sup>−/−</sup> and Rnaseh2<sup>b<sup>2</sup>b<sup>5<sup>1</sup></sup>+/− p53<sup>−/−</sup> MEFS lines were similarly generated from individual whole E10.5 embryos. For assessment of ISG upregulation and cytokine production, MEFS were plated at 2 × 10<sup>5</sup> cells per well in 12-well plates. The following day culture medium was replaced with 800 μl of fresh medium. After a further 20 h, the culture medium was removed for assessment by ELISA to determine CXCL10 and CCL5 concentrations (R&D Systems). RNA was extracted from adherent cells using the RNeasy kit (Qiagen) as per manufacturer’s instructions and included DNase I treatment. Extracted RNA was stored at −80°C until analysis.

**AGS patient cells**

A lymphoblastoid cell line from an AGS patient with the RNASHE2B-A1777 mutation (kindly donated by Professor Yanick Crow, University of Manchester) and non-affected controls were generated from peripheral blood samples by EBV transformation using standard methods. Lymphoblastoid cell lines (LCLs) were maintained in RPMI 1640 supplemented with 15% foetal bovine serum, L-glutamine, 50 U/ml penicillin and 50 μg/ml streptomycin at 37°C, 5% CO2 and normoxic conditions. The A1777/A1777 mutation in the patient cell line was validated using Sanger sequencing.

**Immunoblotting**

Whole-cell lysates were prepared by lysing cells in 50 mM Tris (pH 8), 280 mM NaCl, 0.5% NP-40, 0.2 mM EDTA, 0.2 mM EGTA, 10% glycerol (vol/vol), 1 mM DTT and 1 mM PMSF for 10 min at 4°C. Lysed cells were then diluted 1:1 with 20 mM HEPES (pH 7.9), 10 mM KCl, 1 mM EDTA, 10% glycerol (vol/vol), 1 mM DTT and 1 mM PMSF for an additional 10 min, and extracts were cleared by centrifugation (17,000 g, 5 min, 4°C). Equal amounts of proteins from supernatants (concentrations determined using the Bradford method) were separated by SDS–PAGE on NuPAGE Novex Bis-Tris 4–12% protein gels (Thermo Fisher Scientific) and transferred to PVDF membrane. Membranes were blocked in 5% milk in TBS with 0.2% Tween and probed with antibodies raised against mouse or human recombinant RNase H2, as previously described (Reijns et al., 2012), RNASEH2A (TA306706, Origene) or actin (A2066, Sigma).

**RNase H enzyme assays**

Enzyme activity assays were performed using a FRET-based fluorescent substrate release assay, as previously described.
siRNA knock-down

MEFs were plated overnight at 2 × 10^4 cells per well in a 24-well plate. The following day cells were transfected with short-interfering RNA (siRNA) oligonucleotides targeting cGAS, STING or designed against Luciferase, using Dharmafect 1 in Opti-MEM reduced serum medium (Thermo Fisher Scientific). Appendix Table S4 lists the oligonucleotide sequences. Transfection medium was replaced with 800 μl complete medium after 6 h, and culture medium was removed 48 h after transfection and used for ELISA analysis. Total RNA was extracted from cells as described above. To assess responsiveness to poly(I:C) following siRNA treatment, cells were further transfected with a final concentration of 10 μg/ml of high molecular weight poly(I:C) (InvivoGen) and culture supernatants assessed 22 h later for CCL5 using ELISA.

CRISPR/Cas9 genome editing

Rnaseh2b<sup>-/-</sup> p53<sup>-/-</sup> MEFs were electroporated using the neon transfection system (Invitrogen) with vectors based on pSpCas9n (BB)-2A-GFP, a gift from Feng Zhang (Addgene plasmid # 48140), expressing two guide RNAs designed against the coding part of exon 1 of murine cGAS/Mb21d1 (NM_173386.5), using previously described methods (Ran et al, 2013). Rnaseh2b<sup>-/-</sup> p53<sup>-/-</sup> cGAS<sup>-/-</sup> clones were selected by sizing of PCR products of the targeted region to detect clones in which deletions had occurred; these were subsequently confirmed by Sanger sequencing ensuring out of frame deletions in all alleles. Rnaseh2b<sup>-/-</sup> p53<sup>-/-</sup> cGAS<sup>-/-</sup> MEF clones were identified in parallel to act as controls. An additional functional assay was performed to confirm inactivation of cGAS by assessing cellular responsiveness to transfected dsDNA (1.33 μg/ml final concentration, ISD naked (InvivoGen)) to ensure the absence or presence of functional cGAS, and 2′,3′-cGAMP (2 μg/ml final concentration (InvivoGen)) to confirm the presence of functional STING. Innate immune activation of Rnaseh2b<sup>-/-</sup> p53<sup>-/-</sup> cGAS<sup>-/-</sup> and Rnaseh2b<sup>-/-</sup> p53<sup>-/-</sup> cGAS<sup>-/-</sup> clones was assessed as described above.

Complementation of RNase H2 null MEFs

The Rnaseh2b<sup>-/-</sup> p53<sup>-/-</sup> MEF line used for complementation was previously published and was derived from an E10.5 embryo, resulting from interbreeding Rnaseh2b<sup>+/+</sup> p53<sup>-/-</sup> null MEFs (Reijns et al, 2012). These cells were infected in the presence of 4 μg/ml polybrene with retroviral supernatant from the Phoenix Ecotropic packaging cell line (Swift et al, 2001) transfected with pMSCVpuro, allowing expression of EGFP, Rnaseh2b (NP_080277) or Rnaseh1 (NP_001237394), and selected for stable integration with 2 μg/ml puromycin. Phoenix cells and pMSCVpuro were a kind gift from Dr. Irena Stancheva, University of Edinburgh.

Immunofluorescence

Parental Rnaseh2b<sup>-/-</sup> p53<sup>-/-</sup> MEFs, matching Rnaseh2b<sup>+/+</sup> p53<sup>-/-</sup> controls (Reijns et al, 2012) and complemented Rnaseh2b<sup>-/-</sup> p53<sup>-/-</sup> MEFs (5 × 10^4 cells per well), were plated on coverslips in 6-well plates. After 24 h, non-chromatin bound proteins were extracted using pre-extraction buffer (25 mM HEPES buffer), 2% Triton X-100) with 250 nM substrate in 96-well flat-bottomed plates at 24 ± 2°C. Whole-cell lysates were prepared as described above, and the final protein concentration used per reaction was 100 ng/μl (for DRD:DNA substrate), 50 ng/μl (for RNA:DNA substrate) for MEFs, and 32 or 16 ng/μl, respectively, for LCLs. Fluorescence was read for 100 ms using a VICTOR2 1420 multilabel counter (Perkin Elmer), with a 480-nm excitation filter and a 535-nm emission filter.
pH 7.4, 50 mM NaCl, 1 mM EDTA, 3 mM MgCl₂, 0.3 M sucrose, and 0.5% Triton X-100) for 7 min on ice. Cells were fixed with 4% PFA for 14 min at room temperature (RT). After blocking with 3% FCS in PBS for 30 min at RT, 53BP1 antibody (NB100-904, Novus Biologicals) was added for 1 h at RT. The next day, Alexa Fluor 568 goat anti-rabbit secondary antibody (Life technologies) was applied and incubated for 1 h at RT. Coverslips were mounted using Vectashield antifade mounting medium with DAPI (Vector laboratories) and imaged at RT using a Coolsnap HQ CCD camera (Photometrics) and a Zeiss Axioplan II fluorescence microscope with Plan-neofluar objectives (×40 and ×63) and acquired with iVision software (BioVision Technologies). Scoring was done under blinded conditions.

Statistical analysis

Data were analysed by unpaired t-test for normally distributed quantitative data and Mann–Whitney U-tests for nonparametric data as indicated in the text. One-sample t-tests were employed where parametric data were plotted in terms of percentage of control. Prism (GraphPad Software, Inc) was used throughout.

Author contributions

KJM, PC, LL, ZT, RER, BR, FK, AF, PSD, MAMR performed the experiments. KJM, PC, LL, ZT, EA, RER, BR, GG, MAMR and APJ analysed data. FD, AR and AF developed protocols and provided reagents. KJM, KR, RER, MAMR and APJ planned the project/supervised experiments. KJM, MAMR and APJ wrote the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.
is the metazoan second messenger produced by DNA-activated cyclic
of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases.
*Proc Natl Acad Sci USA* 112: E5699–E5705
is required for lethal autoimmune disease in the Trex-1-deficient mouse
V, Chara O, Lee YA, Hubner N, Bicknell L, Blum S, Krug C, Schmidt F,
Hartlova A, Erttmann SF, Raffi FA, Schmalz AM, Resch U, Anugula S,
Moelling K, Broecker F, Mankan AK, Schmidt T, Chauhan D, Goldeck M,
sensor MDAs-driven autoimmunity and multi-organ development.
*Immunity* 43: 933–944
Rabe B (2013) Aicardi-Goutieres syndrome: clues from the RNase H2 knock-
out mouse. *J Mol Med (Berl)* 91: 1235–1240
engineering using the CRISPR-Cas9 system. *Nat Protoc* 8: 2281–2308
Rehwinkel J, Maelfait J, Bridgeman A, Rigby R, Hayward B, Liberatore RA,
Bieniasz PD, Towers CJ, Moita LF, Crow YJ, Bonthron DT, Reis e Sousa C
(2013) SAMHD1-dependent retroviral control and escape in mice. *EMBO J*
32: 2454–2462.
Rejns MA, Bubeck D, Gibson LC, Graham SC, Bailleis GS, Jones EY, Jackson AP
(2011) The structure of the human RNase H2 complex defines key
interaction interfaces relevant to enzyme function and human disease.
*J Biol Chem* 286: 10530–10539
of ribonucleotides from DNA is essential for mammalian genome integrity
and development. Cell 149: 1008–1022
Rice Gi, Bond J, Aspiu A, Brunette RL, Manfield IW, Carr IM, Fuller JC, Jackson
RM, Lamb T, Briggs TA, Ali M, Gornall H, Couthard LR, Aeby A, Attard-
Montalto SP, Bertini E, Bodemer C, Brockmann K, Bruettin LA, Corry PC,
SAMHD1 as regulator of the innate immune response. *Nat Genet* 41:
829–832
Rice Gi, Kasher PR, Forte GM, Mannion NM, Greenwood SM, Szychkiewicz M,
Dickerson JE, Bhaskar SS, Zamponi M, Briggs TA, Jenkinson EM, Bacino CA,
Battini R, Bertini E, Brogan PA, Bruettin LA, Carpanelli M, De Laet C, de
Goutieres syndrome associated with a type I interferon signature. *Nat Genet*
44: 1243–1248
Rice Gi, Forte GM, Szychkiewicz M, Chase DS, Aeby A, Abdel-Hamid MS,
Ackroyd S, Allcock R, Bailey KM, Balottini U, Barrenies C, Bernard G,
Bodemer C, Botella MP, Cereda C, Chandler KE, Dabydeen L, Dale RC, De
biomarkers in Aicardi-Goutieres syndrome associated with mutations in
TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a
case-control study. *Lancet Neurol* 12: 1159–1169
Rice Gi, del Toro Duany Y, Jenkinson EM, Forte GM, Anderson BH, Ariaudo G,
Bader-Meunier B, Baildam EM, Battini R, Beresford MW, Casarano M,
IFIH1 cause a spectrum of human disease phenotypes associated with
Revuelta A, Davidson DJ, Diebold S, Modis Y, MacDonald AS, Jackson AP
(2014) RNA:DNA hybrids are a novel molecular pattern sensed byTLR9.
*EMBO J* 33: 542–558
by RNase H (type 2) and FEN-1 in cell-free extracts. *Proc Natl Acad Sci U S A*
99: 16654–16659

© 2016 The Authors

The EMBO Journal


© 2016 The Authors

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.